At what age is Cologuard (multitarget stool DNA test) recommended for average-risk individuals?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cologuard (Multitarget Stool DNA Test) Age Recommendations for Average-Risk Individuals

Cologuard screening should begin at age 45 for average-risk individuals and continue through age 75, with individualized decisions for those aged 76-85 based on health status and prior screening history, and discontinuation after age 85. 1, 2

Age to Start Screening with Cologuard

Age 45-49 Years

  • Multiple major guidelines now recommend initiating colorectal cancer (CRC) screening at age 45 for average-risk individuals:

    • American Cancer Society (2018) - qualified recommendation 1
    • US Preventive Services Task Force (2021) - Grade B recommendation 1
    • US Multi-Society Task Force (2022) - weak recommendation 1
    • NCCN Guidelines (2024) - recommendation for all average-risk individuals 1
  • Rationale for starting at age 45:

    • Increasing CRC incidence and mortality in younger adults 1
    • Approximately 43% of early-onset CRC diagnoses occur in individuals aged 45-49 years 1
    • Incidence rates in 45-49 year-olds now match rates previously seen in 50-year-olds when screening was first recommended 1
    • Modeling studies show benefits outweigh harms and costs 1, 3

Age to Stop Screening with Cologuard

Age 75-85 Years

  • Continue screening through age 75 for average-risk adults in good health with life expectancy >10 years 1, 2
  • For ages 76-85: Base decision on:
    • Prior screening history (especially important)
    • Overall health status
    • Life expectancy
    • Patient preferences 1, 2

Age >85 Years

  • Screening should be discontinued after age 85 1
  • Rationale: Overall mortality risk and adverse events associated with follow-up colonoscopy outweigh potential benefits 1

Cologuard-Specific Considerations

  • Cologuard (multitarget stool DNA test) is recommended every 3 years for average-risk individuals 1, 2
  • Performance characteristics:
    • Sensitivity for CRC: 92.3% (higher than FIT at 73.8%)
    • Sensitivity for advanced precancerous lesions: 42.4% (higher than FIT at 23.8%)
    • Specificity: 86.6% (lower than FIT at 94.9%) 2
  • Any positive Cologuard test must be followed up with diagnostic colonoscopy 1, 2

Special Considerations

  • Despite recommendations to begin screening at 45, current uptake remains low - only 19.7% of eligible adults aged 45-49 years were up-to-date on CRC screening in 2021 4
  • Screening rates are particularly low among:
    • Uninsured individuals (7.6%)
    • Those with less than high school education (15.4%)
    • Asian Americans (13.1%) 4
  • For individuals with family history of CRC or advanced adenomas, earlier screening is recommended (typically age 40 or 10 years before youngest affected relative's diagnosis) 2, 5

Clinical Algorithm for Age-Based Screening Decisions

  1. Age 45-75: Offer Cologuard every 3 years (or alternative screening method based on patient preference)
  2. Age 76-85: Assess:
    • Prior screening history (negative prior colonoscopy 10+ years ago suggests lower benefit) 6
    • Comorbidities (severe comorbidities suggest limited benefit)
    • Life expectancy (benefit requires >10 years life expectancy)
  3. Age >85: Discontinue screening regardless of other factors

Remember that any positive Cologuard test requires follow-up with diagnostic colonoscopy, which carries small but real risks that increase with age.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Colorectal Cancer Screening Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

At What Age Should We Stop Colorectal Cancer Screening? When Is Enough, Enough?

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.